Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 301–400 of 930
Long-term follow-up of cytogenetically normal CEBPA-mutated AML
Pastore, F., Kling, D., Hoster, E., Dufour, A. M., Konstandin, N. P., Schneider, S. E., Sauerland, M. C., Berdel, W. E., Büchner, T., Wormann, B. J., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0055-7 · Cited by 49
Self-citationTranscriptional regulation by DNA methylation
Poetsch, A. R., & Plass, C. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.010 · Cited by 55
Insertions and Deletions (Indels)
Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00009-5 · Cited by 64
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Jakobsen, J. S., Laursen, L. G., Schuster, M. B., Pundhir, S., Schoof, E. M., Ge, Y. C., D’Altri, T., Vitting‐Seerup, K., Rapin, N., Gentil, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw4304 · Cited by 49
Epigenetic regulation and molecular characterization of C/EBPα in pancreatic cancer cells
Kumagai, T., Akagi, T., Desmond, J. C., Kawamata, N., Gery, S., Imai, Y., Song, J. H., Gui, D., Said, J., & Koeffler, H. P. (2009) · International Journal of Cancer · doi:10.1002/ijc.23994 · Cited by 47
Ovcharenko, D., Stölzel, F., Poitz, D. M., Fierro, F. A., Schaich, M. A., Neubauer, A., Kelnar, K., Davison, T. S., Müller‐Tidow, C., Thiede, C., et al. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.07.008 · Cited by 50
Concise Review: Erythroid Versus Myeloid Lineage Commitment: Regulating the Master Regulators
Wolff, L., & Humeniuk, R. (2013) · Stem Cells · doi:10.1002/stem.1379 · Cited by 41
Hox gene Dysregulation in Acute Myeloid Leukemia
Braekeleer, E. D., Douet‐Guilbert, N., Basinko, A., Bris, M. L., Morel, F., & Braekeleer, M. D. (2014) · Future Oncology · doi:10.2217/fon.13.195 · Cited by 51
Pathak, A. B., Seipel, K., Pemov, A., Dewan, R., Brown, C. D., Ravichandran, S., Luke, B. T., Malasky, M., Suman, S., Yeager, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.130799 · Cited by 49
Self-citationHashimoto, A., Gao, C., Mastio, J., Kossenkov, A. V., Abrams, S. I., Purandare, A. V., Desilva, H., Wee, S., Hunt, J., Jure‐Kunkel, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1229 · Cited by 49
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
Setten, R. L., Lightfoot, H. L., Habib, N., & Rossi, J. J. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180611093428 · Cited by 49
Role of Biomarkers in FLT3 AML
Nitika, Wei, J., & Hui, A. (2022) · Cancers · doi:10.3390/cancers14051164 · Cited by 48
Wang, Q., Cleaves, R., Kummalue, T., Nerlov, C., & Friedman, A. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206360 · Cited by 55
Shih, L.-Y., Liang, D.-C., Huang, C.-F., Jh, W., Lin, T.-L., Wang, P.-N., Dunn, P., Kuo, M.-C., & Tang, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404124 · Cited by 48
Fuchs, O., Provazníková, D., Kocova, M., Kostečka, A., Cvekova, P., Neuwirtová, R., Kobylka, P., Čermák, J., Březinová, J., Schwarz, J., et al. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.11.005 · Cited by 48
Transcriptional mechanisms regulating myeloid-specific genes
Skalnik, D. G. (2002) · Gene · doi:10.1016/s0378-1119(02)00387-6 · Cited by 58
Loomis, K. D., Zhu, S., Yoon, K., Johnson, P. F., & Smart, R. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0139 · Cited by 54
Schepers, H., Wierenga, A. T. J., van Gosliga, D., Eggen, B. J. L., Vellenga, E., & Schuringa, J. J. (2007) · Blood · doi:10.1182/blood-2006-10-052175 · Cited by 53
Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias
Chim, C. S., Wong, A. S. Y., & Kwong, Y. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0744-8 · Cited by 49
“Other genetic aberrations that specifically occur in the M2 phenotype include the AML1/ETO fusion, and mutation and occasionally methylation of the gene CEBPa [22, 23].”
BackgroundMolecular cytogenetic aspects of hematological malignancies: Clinical implications
Chen, Z., & Sandberg, A. A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10689 · Cited by 52
“Another study of patients with ANLL and normal karyotypes identified dominant-negative mutations of the tumor suppressor gene C/EBPa in 5% of patients with normal karyotypes [Pabst et al., 2001].”
BackgroundAbnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia
Tenen, D. G. (2001) · Leukemia · doi:10.1038/sj.leu.2402088 · Cited by 47
Self-citationComprehensive genotypic analysis of leukemia: clinical and therapeutic implications
Kelly, L., Clark, J., & Gilliland, D. G. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00003 · Cited by 47
Getting a handle on hereditary CEBPA mutations
Dinardo, C. D. (2015) · Blood · doi:10.1182/blood-2015-07-657908 · Cited by 46
The Multiple Roles of Microrna-223 in Regulating Bone Metabolism
Xie, Y., Zhang, L., Gao, Y., Ge, W., & Tang, P. (2015) · Molecules · doi:10.3390/molecules201019433 · Cited by 47
“In turn, miR-223 expression is regulated by the competition between NFIA and CCAAT/enhancerbinding protein-α (C/EBPα) [45], which is known to function as an activator of target genes through binding directly to the consensus DNA sequence [46].”
BackgroundData-Driven Prediction and Design of bZIP Coiled-Coil Interactions
Potapov, V., Kaplan, J. B., & Keating, A. E. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004046 · Cited by 45
“Developing reagents that can selectively target bZIPs, and thus inhibit their DNA binding function, may be useful for further elucidating biological function and for testing the potential of bZIPs as therapeutic targets [30–35].”
Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia
Tiesmeier, J., Czwalinna, A., Müller‐Tidow, C., Krauter, J., Serve, H. L., Heil, G., Ganser, A., & Verbeek, W. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04618.x · Cited by 46
“Mutations in the N-terminal part of the protein result in the dominant expression of the short C/EBP a p30 isoform, which lacks the transactivation domain 1 (TAD 1) and has a dominant- negative effect on transcription (Lin et al, 1993; Pabst et al, 2001).”
BackgroundGozzini, A., Rovida, E., Sbarba, P. D., Galimberti, S., Santini, V., & Galimbert, S. (2003) · PubMed · Cited by 53
CEBPα mutations in childhood acute myeloid leukemia
Liang, D. C., Shih, L. Y., Huang, C. F., Hung, I. J., Yang, C. P., Liu, H.-C., Jaing, T. H., Wang, L.-Y., & Chang, W. H. (2004) · Leukemia · doi:10.1038/sj.leu.2403608 · Cited by 49
Zhai, Y., Singh, P., Dolnik, A., Brázda, P., Atlasy, N., Gaudio, N. D., Döhner, K., Döhner, H., Minucci, S., Martens, J. H. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01635-4 · Cited by 46
“To gain insight into the 31 clonal heterogeneity of diagnosis (Dx) and relapse (Re) pairs, we employed whole-exome 32 sequencing and single-cell RNA-seq to longitudinally profile two t(8;21) (AML1-ETO = 33 RUNX1-RUNX1T1), and four FLT3-ITD AML cases.”
BackgroundMethodInfluentialAcute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy
Wang, M. L., & Bailey, N. G. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0203-ra · Cited by 51
Paz‐Priel, I., Houng, S., Dooher, J. E., & Friedman, A. D. (2011) · Blood · doi:10.1182/blood-2010-07-294470 · Cited by 50
In, K., Zaini, M. A., Müller, C., Warren, A. J., Lindern, M. V., & Calkhoven, C. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw005 · Cited by 49
Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marando, L., & Huntly, B. J. P. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00918-7 · Cited by 49
The Hypoxia-Inducible Factor–C/EBPα Axis Controls Ethanol-Mediated Hepcidin Repression
Anderson, E. R., Taylor, M., Xue, X., Martin, A., Moons, D. S., Omary, M. B., & Shah, Y. M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00723-12 · Cited by 42
Cleaves, R., Wang, Q., & Friedman, A. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207172 · Cited by 50
“…diminished C/EBPa activity contributes to myeloid progenitor transformation via reduction of their differentiation potential, monoallelic point mutations were recently identified in the CEBPA gene in approximately 5% of acute myeloid leukemia (AML) cases (Pabst et al., 2001; Gombart et al., 2002).”
BackgroundMethodInfluentialAML1 Interconnected Pathways of Leukemogenesis: MOLECULAR BIOLOGY AND GENETICS
Michaud, J., Scott, H. S., & Escher, R. (2003) · Cancer Investigation · doi:10.1081/cnv-120018821 · Cited by 53
Molecular diagnostics in acute leukemias
Bacher, U., Schnittger, S., Haferlach, C., & Haferlach, T. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.324 · Cited by 44
Self-citationGroßmann, V., Schnittger, S., Schindela, S., Klein, H., Eder, C., Dugas, M., Kern, W., Haferlach, T., Haferlach, C., & Kohlmann, A. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.09.001 · Cited by 44
Self-citationWen, X., Lin, J., Yang, J. C., Yao, D., Deng, Z., Tang, C.-Y., Xiao, G.-F., Yang, L., Ma, J., Hu, J., et al. (2014) · PubMed Central · Cited by 47
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 48
The E2F1-miRNA Cancer Progression Network
Knoll, S., Emmrich, S., & Pützer, B. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_8 · Cited by 50
Bararia, D., Trivedi, A. K., Zada, A. A. P., Greif, P. A., Mulaw, M. A., Christopeit, M., Hiddemann, W., Bohlander, S. K., & Behre, G. (2008) · Leukemia · doi:10.1038/sj.leu.2405101 · Cited by 47
Self-citationSchuster, C., Forster, K., Dierks, H., Elsässer, A., Behre, G., Simon, N., Danhauser-Riedl, S., Hallek, M., & Warmuth, M. (2003) · Blood · doi:10.1182/blood-2002-01-0043 · Cited by 43
Self-citationMultistep tumorigenesis in peripheral T cell lymphoma
Sakata‐Yanagimoto, M. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1738-8 · Cited by 44
Tseng, H. H., Hwang, Y., Yeh, K., Chang, J., Chen, Y., & Yu, H. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0448-5 · Cited by 43
Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia
Windisch, R., Pirschtat, N., Kellner, C., Chen-Wichmann, L., Lausen, J., Humpe, A., Krause, D. S., & Wichmann, C. W. (2019) · Cancers · doi:10.3390/cancers11030311 · Cited by 48
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
Panuzzo, C., Signorino, E., Calabrese, C., Ali, M. S., Petiti, J., Bracco, E., & Cilloni, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030802 · Cited by 47
Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity
Chen, X., Zhou, W., Song, R., Liu, S., Wang, S., Chen, Y., Gao, C., He, C., Xiao, J., Zhang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl5220 · Cited by 44
Theilgaard‐Mönch, K., Pundhir, S., Reckzeh, K., Su, J., Tapia, M. C., Furtwängler, B., Jendholm, J., Jakobsen, J. S., Hasemann, M. S., Knudsen, K. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31332-1 · Cited by 47
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Bouligny, I. M., Maher, K. R., & Grant, S. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100996 · Cited by 47
Cooper, S., Parke, H. G., & Friedman, A. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126385 · Cited by 46
Tsiftsoglou, A. S., Bonovolias, I. D., & Tsiftsoglou, S. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.001 · Cited by 50
“Several groups have reported two types of mutations in C/EBPα with a notable frequency in AML patients (Pabst et al., 2001a, 2001b; Preudhomme et al., 2002; Gombart et al., 2002; Snaddon et al., 2003; Nerlov, 2004).”
BackgroundTranscriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein
Yang, G., Khalaf, W. F., van de Locht, L. T., Jansen, J. H., Gao, M., Thompson, M. A., van der Reijden, B. A., Gutmann, D. H., Delwel, R., Clapp, D. W., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5869-5879.2005 · Cited by 45
Cheng, C. K., Li, L., Cheng, S. H., Ng, K., Chan, N. P. H., Ip, R. K. L., Wong, R. S. M., Shing, M. M. K., Li, C. K., & Ng, M. H. L. (2011) · Blood · doi:10.1182/blood-2011-05-354712 · Cited by 42
Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M., Nencioni, A., Gobbi, M., & Cea, M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.006 · Cited by 47
“[85] Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al.”
BackgroundNucleolar retention of a translational C/EBPα isoform stimulates rDNA transcription and cell size
Müller, C., Bremer, A., Schreiber, S., Eichwald, S., & Calkhoven, C. F. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.404 · Cited by 46
“In the haematopoietic system, C/ EBPa is required for the differentiation of myelomonocytic cells, and mutations in the CEBPA gene are considered to be critically involved in the etiology of about 10% of human acute myeloid leukemia (AML) (Nerlov, 2004; Kirstetter et al, 2008).”
Fröhling, S., Schlenk, R. F., Krauter, J., Thiede, C., Ehninger, G., Haase, D. T., Harder, L., Kreitmeier, S., Scholl, C., Caligiuri, M. A., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20152 · Cited by 43
“…in adults who have acute myeloid leuke- mia (AML): N-terminal, dominant-negative frame- shift mutations and C-terminal in-frame mutations (Pabst et al., 2001b; Gombart et al., 2002; Preud- homme et al., 2002; Snaddon et al., 2003; Van Waalwijk Van Doorn-Khosrovani et al.,…”
BackgroundDisruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation
Wurm, A. A., Zjablovskaja, P., Kardosova, M., Gerloff, D., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Benoukraf, T., Fricke, S., Hilger, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00032-6 · Cited by 40
Self-citationKharfan‐Dabaja, M. A., Labopin, M., Bazarbachi, A. A., Hamladji, R. M., Blaise, D., Socié, G., Lioure, B., Bermúdez, A., López‐Corral, L., Or, R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.133 · Cited by 40
Lasa, A., Carnicer, M. J., Aventin, A. M., Estivill, C., Brunet, S., Sierra, J., & Nomdedeu, J. F. (2004) · Leukemia · doi:10.1038/sj.leu.2403377 · Cited by 40
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
Schardt, J., Eyholzer, M., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00870.x · Cited by 41
Self-citationKatzerke, C., Madan, V., Gerloff, D., Bräuer-Hartmann, D., Hartmann, J.-U., Wurm, A. A., Müller-Tidow, C., Schnittger, S., Tenen, D. G., Niederwieser, D., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472183 · Cited by 38
Self-citationAML through the prism of molecular genetics
Charrot, S., Armes, H., Rio‐Machín, A., & Fitzgibbon, J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16356 · Cited by 41
“The first three mutated genes reported in adult AML, FLT3, NPM1 and CEBPA (Kiyoi et al., 1997; Kiyoi et al., 1999; Pabst et al., 2001; Falini et al., 2005; Noguera et al., 2005), have been extensively studied and serve as excellent exemplars for the complexity faced in genetic interpretation.”
BackgroundRegulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells
Heckman, C. A., Wheeler, M. A., & Boxer, L. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206639 · Cited by 41
“C/EBPa functions as a tumor suppressor in myeloid cells by promoting differentiation and growth arrest (Pabst et al., 2001; Tenen, 2001; Behre et al., 2002).”
BackgroundDrugging the unfolded protein response in acute leukemias
Masouleh, B. K., Chevet, É., Panse, J., Jost, E., O'Dwyer, M. E., Bruemmendorf, T., & Samali, A. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0184-7 · Cited by 38
“Mechanistically, for instance, transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) [40] is frequently deregulated by genomic mutations causing maturation defects [41, 42].”
BackgroundPaz‐Priel, I., Ghosal, A., Kowalski, J., & Friedman, A. D. (2008) · Leukemia · doi:10.1038/leu.2008.297 · Cited by 40
The changing paradigm of prognostic factors in acute myeloid leukaemia
Grimwade, D. J. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.10.004 · Cited by 37
“The myeloid transcription factor, CEBPA (CCAAT Enhancer Binding Protein Alpha) was the next important prognostically relevant mutational target to be identified, mutated in w10% of AML [10].”
BackgroundUsing cell fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation
Huang, A. C., Hu, L., Kauffman, S. A., Zhang, W., & Shmulevich, I. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-20 · Cited by 40
“C/EBP is crucial for the process of granulopoiesis, and its aberrant expression in acute myeloid leukemia is well-studied [63-66].”
BackgroundVergez, F., Largeaud, L., Bertoli, S., Nicolau-Travers, M.-L., Rieu, J., Vergnolle, I., Saland, E., Sarry, A., Tavitian, S., Huguet, F., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00712-7 · Cited by 40
Novel transcription factors in human CD34 antigen–positive hematopoietic cells
Gomes, I., Sharma, T., Edassery, S. L., Fulton, N. C., Mar, B. G., & Westbrook, C. A. (2002) · Blood · doi:10.1182/blood.v100.1.107 · Cited by 40
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2002-12-3903 · Cited by 37
Self-citationRegulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review)
Song, G., Wang, L., BI, K., & Jiang, G. (2015) · Oncology Reports · doi:10.3892/or.2015.3848 · Cited by 38
“Among these mutations, N-terminal frameshift mutations prematurely truncate the full-length p42 form while preserving the p30 form, with the latter inhibiting the remaining wild-type C/EBPα p42 protein in a dominant-negative manner (12).”
BackgroundA Clinical Grade Sequencing-Based Assay for CEBPA Mutation Testing
Behdad, A., Weigelin, H. C., Elenitoba‐Johnson, K. S. J., & Betz, B. L. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.09.007 · Cited by 36
An evolutionarily conserved PTEN-C/EBPα-CTNNA1 axis controls myeloid development and transformation
Fu, C., Zhu, K.-Y., Mi, J., Liu, Y., Murray, S. T., Fu, Y., Ren, C., Dong, Z., Liu, Y., Dong, M., et al. (2010) · Blood · doi:10.1182/blood-2009-11-255778 · Cited by 38
Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia
Reckzeh, K., & Cammenga, J. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0573-1 · Cited by 43
Pal, P., Lochab, S., Kanaujiya, J. K., Kapoor, I., Sanyal, S., Behre, G., & Trivedi, A. K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.120 · Cited by 38
Self-citationThe emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML
Kaeferstein, A., Krug, U. O., Tiesmeier, J., Aivado, M. A., Faulhaber, M., Stadler, M., Krauter, J., Germing, U., Hofmann, W.-K., Koeffler, H. P., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402805 · Cited by 36
C/EBPα redirects androgen receptor signaling through a unique bimodal interaction
Zhang, J., Gonit, M., Salazar, M. D., Shatnawi, A. A., Shemshedini, L., Trumbly, R. J., & Ratnam, M. (2009) · Oncogene · doi:10.1038/onc.2009.373 · Cited by 39
“C/EBPa also acts as a tumor suppressor (Watkins et al., 1996; Burel et al. 2001; Pabst et al., 2001a, b; Halmos et al., 2002; ; Gery et al., 2005; Schuster and Porse, 2006; Loomis et al., 2007).”
BackgroundCREB engages C/EBPδ to initiate leukemogenesis
Tregnago, C., Manara, E., Zampini, M., Bisio, V., Borga, C., Bresolin, S., Aveic, S., Germanò, G., Basso, G., & Pigazzi, M. (2016) · Leukemia · doi:10.1038/leu.2016.98 · Cited by 35
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex
Schmidt, L., Heyes, E. C., Scheiblecker, L., Eder, T., Volpe, G., Frampton, J., Nerlov, C., Valent, P., Grembecka, J. E., & Grebien, F. (2019) · Leukemia · doi:10.1038/s41375-019-0382-3 · Cited by 35
CEBPA methylation and mutation in myelodysplastic syndrome
Wen, X., Hu, J., Yang, J. C., Qian, W., Yao, D., Deng, Z., Zhang, Y., Zhu, X., Guo, H. Y., Lin, J., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0605-z · Cited by 37
Control of ribosomal RNA synthesis by hematopoietic transcription factors
Charles Antony, A., George, S. S., Blum, J., Somers, P., Thorsheim, C. L., Wu-Corts, D. J., Ai, Y., Gao, L., Lv, K., Tremblay, M. G., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.027 · Cited by 36
Stelljes, M., Corbacioglu, A., Schlenk, R. F., Döhner, K., Frühwald, M., Rössig, C., Ehlert, K., Silling, G., Müller‐Tidow, C., Juergens, H., et al. (2011) · Leukemia · doi:10.1038/leu.2011.64 · Cited by 35
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPα
Ferrari‐Amorotti, G., Keeshan, K., Zattoni, M., Guerzoni, C., Iotti, G., Cattelani, S., Donato, N. J., & Calabretta, B. (2006) · Blood · doi:10.1182/blood-2006-01-011833 · Cited by 38
FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics
Wang, L., Xu, W., Meng, H., Qian, W., Mai, W., Tong, H., Mao, L., Tong, Y., Qian, J., Lou, Y., et al. (2010) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1000052 · Cited by 35
“In recent years, some somatic alterations have been identified in patients with AML (Schichman et al., 1994; Nakao et al., 1996; Pabst et al., 2001; Falini et al., 2005).”
BackgroundDhawan, P., Weider, R., & Christakos, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803602200 · Cited by 35
Asou, H., Gombart, A. F., Takeuchi, S., Tanaka, H., Tanioka, M., Matsui, H., Kimura, A., Inaba, T., & Koeffler, H. P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10161 · Cited by 37
“In AML M2 with t(8; 21)(q22;q22), C/EBP -dependent activation of its own promoter was blocked by the AML1-ETO fusion protein, and expression of C/EBP protein was not detectable in t(8;21)-AML samples (Pabst et al., 2001b).”
BackgroundMethodInfluentialA Comparison of Two Methods for Screening CEBPA Mutations in Patients with Acute Myeloid Leukemia
Ahn, J.-Y., Seo, K., Weinberg, O. K., Boyd, S. D., & Arber, D. A. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080121 · Cited by 35
Nakao, M., Horiike, S., Fukushima‐Nakase, Y., Nishimura, M., Fujita, Y., Taniwaki, M., & Okuda, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04966.x · Cited by 34
“Similarly, MDS-related mutations of another myeloid transcription factor, CCAAT/enhancer binding protein alpha, are known to be often caused by insertiontype mutations (Pabst et al, 2001; Kaeferstein et al, 2003).”
BackgroundDeregulated transcription factors in leukemia
Shima, Y., & Kitabayashi, I. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0905-9 · Cited by 36
Towards a Better Understanding of Cohesin Mutations in AML
Cuartero, S., Innes, A. J., & Merkenschlager, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00867 · Cited by 34
“mutations that prevent cell cycle arrest and apoptosis such as TP53 (4), and mutations that hinder differentiation such as in the transcription factors RUNX1 or C/EBPα (5, 6).”
BackgroundZebrafish Cancer Predisposition Models
Kobar, K., Collett, K., Prykhozhij, S. V., & Berman, J. N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.660069 · Cited by 39
Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia
Yamato, G., Kawai, T., Shiba, N., Ikeda, J., Hara, Y., Ohki, K., Tsujimoto, S.-I., Kaburagi, T., Yoshida, K., Shiraishi, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005381 · Cited by 36
Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid Leukemia
Zhao, X., Huang, X., Wang, X., Wu, Y., Eisfeld, A., Schwind, S., Gallego‐Perez, D., Boukany, P. E., Marcucci, G. I., & Lee, L. J. (2015) · Advanced Science · doi:10.1002/advs.201500111 · Cited by 34
The Role of Stem Cell Factor SALL4 in Leukemogenesis
Gao, C., Kong, N. R., & Chai, L. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.110 · Cited by 34
Fuchs, O. (2007) · Folia Biologica · doi:10.14712/fb2007053030097 · Cited by 36
Molecular markers in acute myeloid leukaemia
Kühnl, A., & Grimwade, D. J. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1123-9 · Cited by 42
ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα
Gonzalez, D., Luyten, A., Bartholdy, B., Zhou, Q., Adamcova, M. K., Ebralidze, A. K., Swanson, K. D., Radomska, H. S., Zhang, P., Kobayashi, S. S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811109 · Cited by 33
Self-citationRARα-PLZF oncogene inhibits C/EBPα function in myeloid cells
Girard, N., Tremblay, M. R., Humbert, M., Grondin, B., Haman, A., Labrecque, J., Chen, B., Zhu, C. H., Chen, S., & Hoang, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310067110 · Cited by 33
Nanri, T., Uike, N., Kawakita, T., Iwanaga, E., Mitsuya, H., & Asou, N. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20734 · Cited by 37
“Two overlapping primer pairs were the same as those designed by Pabst et al. (2001) and used to amplified the entire coding region of human CEBPA: PP1F 50- TCGCCATGCCGGGAGAACTCTAAC-30 (nucleotides 120–143) and PP1R 50-CTGGTAAGGGAAGAGGCCGGCCAG-30 (nucleotides 692–669), PP2F…”
BackgroundMethod
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.